JNJ · 10-Q · 2026Q2

JOHNSON & JOHNSON

Filed 2026-07-23 · Healthcare · View original filing on EDGAR

Ranked Events

• Accrued Legal and RegulatoryImportance 89 · Surprise 82
  Other expense for fiscal six months 2026 was $0.6 billion compared with $7.2 billion of income in 2025, a $7.8 billion year-over-year swing. Fiscal six months 2026 included $0.8 billion of charges for talc matters,…
• Immunology Competition PressureImportance 81 · Surprise 64
  Innovative Medicine immunology sales declined 6.2% to $7.2 billion in fiscal six months 2026, including an 8.1% operational decline. STELARA sales fell 57.4% because of biosimilar competition, increasing adoption of…
• Revenue Performance and MixImportance 75 · Surprise 64
  Worldwide sales increased 8.2% to $49.4 billion in fiscal six months 2026 from $45.6 billion, including 6.0% operational growth and a 2.2% favorable currency impact. Innovative Medicine sales rose 9.4% to $31.8…
• Talc Litigation SettlementImportance 71 · Surprise 82
  Johnson & Johnson recorded $0.8 billion of charges for talc matters during the fiscal six months of 2026, including $0.4 billion in the second quarter. The prior-year comparison included approximately $7.0 billion…
• Segment ProfitabilityImportance 69 · Surprise 64
  Fiscal six-month consolidated earnings before tax decreased to $12.7 billion, or 25.8% of sales, from $20.1 billion, or 44.1%, primarily because fiscal 2025 included a $7.0 billion talc reserve reversal. Innovative…
• Oncology Product GrowthImportance 65 · Surprise 48
  Innovative Medicine oncology sales increased 19.9% to $14.4 billion in fiscal six months 2026, with 16.9% operational growth. DARZALEX grew 20.6% on strong share gains and market growth, while CARVYKTI increased 55.1%…
• Neuroscience Demand GrowthImportance 59 · Surprise 48
  Neuroscience sales increased 22.0% to $4.5 billion in fiscal six months 2026, with 20.5% operational growth. SPRAVATO sales grew 43.2%, driven by increased physician and patient demand. CAPLYTA benefited from continued…
• Supply Chain Tariff ImpactImportance 50 · Surprise 58
  Tariffs increased cost pressure in the MedTech business during both the fiscal six months and second quarter of 2026. Management identified tariffs included in cost of products sold as a primary reason MedTech income…
• MedTech Product And Procedure TrendsImportance 49 · Surprise 32
  MedTech achieved 4.5% sales growth in the second quarter of 2026, including 3.6% operational growth, with international sales up 5.2% and U.S. sales up 3.9%. Electrophysiology benefited from procedure growth,…
• Geographic Market CommentaryImportance 49 · Surprise 32
  Worldwide sales increased 8.2% to $49.4 billion in fiscal six months 2026, including 6.0% operational growth and a 2.2% favorable currency impact. U.S. sales grew 7.8% to $27.9 billion, while international sales rose…
• Capital Return ProgramImportance 49 · Surprise 6
  Johnson & Johnson used $6.4 billion for shareholder dividends and $4.2 billion to repurchase common stock during fiscal six months 2026. The Company declared regular cash dividends of $1.34 per share on April 14 and…
• Orthopaedics SeparationImportance 46 · Surprise 42
  Johnson & Johnson announced in October 2025 that it intended to separate its Orthopaedics business. The Company continues to evaluate multiple paths for the separation and targets completion within 18 to 24 months of…
• Headcount / RestructuringImportance 46 · Surprise 42
  Johnson & Johnson initiated a supply chain restructuring program in the fiscal second quarter of 2026 to exit certain Innovative Medicine manufacturing locations and streamline operations. The program is expected to be…
• Liquidity and Cash PositionImportance 42 · Surprise 14
  Cash and cash equivalents increased to $20.4 billion at June 28, 2026, from $19.7 billion at fiscal year-end 2025. Fiscal six-month operating cash flow was $11.1 billion, while investing activities used $2.2 billion…
• Income Tax Rate ChangesImportance 25 · Surprise 32
  The worldwide effective income tax rate declined to 15.5% for fiscal six months 2026 from 17.8% in fiscal six months 2025. The 2.3 percentage-point reduction represents an approximately 13% year-over-year decrease in…
• FX / Currency ImpactImportance 24 · Surprise 14
  Currency fluctuations increased worldwide sales by 2.2% during the fiscal six months of 2026. International company sales benefited from a 5.1% currency impact, while Europe and the Western Hemisphere excluding the…

Revenue by Product (in millions)

Revenue by Geography (in millions)